Citations

Clear

479 citation(s) found for "Tobias, JS".

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Tur, Carmen , Otero‐Romero, Susana , Amato, Maria Pia , Derfuss, Tobias , Pauli, Franziska Di , Abboud, Hesham , Achiron, Anat , Casanova, Jean‐Laurent , Clifford, David B. , Fonderico, Mattia , Gouider, Riadh , Hacohen, Yael , Kappos, Ludwig , Ladeira, Filipa , Louapre, Céline , Magyari, Melinda , Papeix, Caroline , Piehl, Fredrik , Ruíz-Camps, Isabel , Selmaj, Krzysztof , Simpson, Steve , Sıva, Aksel , Vaknin‐Dembinsky, Adi , Weinshenker, Brian G. , Winkelmann, Alexander, Rodas, María Isabel Zuluaga , Tintoré, Mar , Amato, Maria Pia , Derfuss, Tobias , Abboud, Hesham , Achiron, Anat , Dobson, Ruth , Filippi, Massimo , Fitzgerald, Kathryn C , Fonderico, Mattia , Hellwig, Kerstin , Hemmer, Bernhard , Ladeira, Filipa , Lebrun‐Frénay, Christine , Magyari, Melinda , Oreja-Guevara, Celia , Pandit, Lekha , Papeix, Caroline , Portaccio, Emilio , Simpson-Yap, Steve , Siva, Aksel , Sormani, Maria P , Vukusic, Sandra , Wiendl, Heinz , Tintoré, Mar , Weinshenker, Brian G , Casanova, Jean Laurent , Hacohen, Yael , Dubessy, Anne‐Laure , Iacobaeus, Ellen , Mycko, Marcin P. , Bellinvia, Angelo , Boyко, Alexey , Farez, Mauricio , Filippi, Massimo , Mehling, Matthias , Oreja‐Guevara, Celia , Pandit, Lekha , Sørensen, Per Soelberg , Sormani, Maria Pia , Trojano, María , Wiendl, Heinz , Stankoff, Bruno

Mayo Clinic

Multiple Sclerosis Journal | February 24, 2022 | Volume: 28 | Issue: 9 | Pages: 1424-1456

10.1177/13524585211069068 | PMID 35196927 Get It

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
Slowing gait speed precedes cognitive decline by several years
Blennow, Kaj , Skoog, Johan , Guo, Xinxin , Sacuiu, Simona , Zettergren, Anna , Kern, Silke , Skillbäck, Tobias Borgh , Zetterberg, Henrik , Rydén, Lina , Wetterberg, Hanna , Mielke, Michelle M. , Skoog, Ingmar

Mayo Clinic

Alzheimer's & Dementia | February 10, 2022 | Volume: 18 | Issue: 9 | Pages: 1667-1676

10.1002/alz.12537 | PMID 35142034 Get It

Abstract Introduction In this longitudinal study, we aimed to examine if slowing gait speed preceded cognitive decline and correlated with brain amyloidosis. Methods The sample (n = 287) was derived from the Gothenburg H70 Birth Cohort Studies, with follow‐ups between 2000 and 2015. Gait speed was measured by indoor walk, and cognition using the Clinical Dementia Rating (CDR) score. All participants had CDR = 0 at baseline. Some participants had data on cerebrospinal fluid (CSF) amyloid beta (Aβ) 1‐42 concentrations at the 2009 examination. Results Gait speed for participants who worsened in CDR score during follow‐up was slower at most examinations. Baseline gait speed could significantly predict CDR change from baseline to follow‐up. Subjects with pathological CSF Aβ 1‐ 42 concentrations at the 2009 visit had lost more gait speed compared to previous examinations. Discussion Our results indicate that gait speed decline precedes cognitive decline, is linked to Alzheimer's pathology, and might be used for early detection of increased risk for dementia development.
Safety and efficacy of the JAK-inhibitor tofacitinib in patients with primary sclerosing cholangitis: a multicentre, retrospective study
Schregel, Ida , Eaton, John E. , Jones, Randall, Ramos, GuilhermePiovezani, Ioannou, Stephanie , Chazouillères, Olivier , Joshi, Deepak , Zigmond, Ehud , Shibolet, Oren , Zhou, Taotao , Ramos, Guilherme Piovezani , Levy, Cynthia , Culver, Emma , Färkkilâ, Martti , Müller, Tobias , Nayagam, Jeremy Shanika , Drenth, Joost P.H. , Hoentjen, Frank , Geerts, Anja M. , Weismüller, Tobias J. , Schramm, Christoph

Mayo Clinic

Zeitschrift für Gastroenterologie | February 4, 2022 | Volume: 60 | Issue: 01 | Pages: e18-e18

10.1055/s-0041-1740704 Get It

A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism
DelConte, Anthony , Papangkorn, Kongnara , Kim, Kilyoung, Bruno, Benjamin, Chidambaram, Nachiappan, Khera, Mohit , Köhler, Tobias , Miner, Martin , Dobs, Adrian S. , Patel, Mahesh, Goldstein, Irwin

Mayo Clinic

Andrology | January 7, 2022 | Volume: 10 | Issue: 4 | Pages: 669-676

10.1111/andr.13153 | PMID 34994093 Get It

AbstractBackgroundMale hypogonadism (testosterone level < 300 ng/dl) is a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone. Most marketed testosterone replacement therapy products often require multiple dose adjustment clinic visits to achieve the desired, eugonadal testosterone levels.ObjectiveTo evaluate the efficacy and safety of a novel oral testosterone undecanoate therapy for the treatment of hypogonadism.Material and methodsNinety‐five (N = 95) hypogonadal men were enrolled in this open‐label, single‐arm, multicenter study in the United States (NCT03242590). Subjects received 225 mg of oral testosterone undecanoate (TLANDO) twice a day for 24 days without dose adjustment. Primary efficacy was percentages of subjects who achieved mean 24‐h testosterone levels within the eugonadal range and secondary efficacies were evaluated based on the upper limit of lab normal range of testosterone concentration.ResultsSubjects enrolled were on average age of 56 years, with about 17% of subjects older than 65 years. The mean body mass index was 32.8 kg/m2. The baseline mean total testosterone values were below the normal range (202 ± 74 ng/dl). Post‐treatment with 450 mg testosterone undecanoate daily dose without dose adjustment, 80% of subjects (95% confidence interval of 72%–88%) achieved a testosterone Cavg in the normal range and restored testosterone levels to mean testosterone Cavg of 476 ± 184 ng/dl at steady state. Testosterone restoration was comparable to other approved testosterone replacement therapy products. TLANDO was well tolerated with no deaths, no drug‐related serious adverse events, and no hepatic adverse events.Discussion and conclusionsTLANDO restored testosterone levels to the normal range in the majority of hypogonadal males. This new oral testosterone replacement therapy can provide an option for no‐titration oral testosterone replacement therapy. This therapy has the potential to improve patient compliance in testosterone replacement therapy.
Clinico‐radiological features, molecular spectrum, and identification of prognostic factors in developmental and epileptic encephalopathy due to inosine triphosphate pyrophosphatase (ITPase) deficiency
Scala, Marcello , Wortmann, Saskia B. , Kaya, Namik , Stellingwerff, Menno D., Pistorio, Angela, Glamuzina, Emma, Karnebeek, Clara D., Skrypnyk, Cristina, Iwanicka‐Pronicka, Katarzyna, Piekutowska‐Abramczuk, Dorota, Ciara, Elżbieta, Tort, Frederic, Sheidley, Beth, Poduri, Annapurna, Jayakar, Parul, Jayakar, Anuj, Upadia, Jariya, Walano, Nicolette, Haack, Tobias B., Prokisch, Holger, Aldhalaan, Hesham, Karimiani, Ehsan G., Yildiz, Yilmaz, Ceylan, Ahmet C., Santiago‐Sim, Teresa, Dameron, Amy, Yang, Hui, Toosi, Mehran B., Ashrafzadeh, Farah, Akhondian, Javad, Imannezhad, Shima, Mirzadeh, Hanieh S., Maqbool, Shazia, Farid, Aisha, Al‐Muhaizea, Mohamed A., Alshwameen, Meznah O., Aldowsari, Lama, Alsagob, Maysoon, Alyousef, Ashwaq, AlMass, Rawan, AlHargan, Aljouhra, Alwadei, Ali H., AlRasheed, Maha M., Colak, Dilek, Alqudairy, Hanan, Khan, Sameena, Lines, Matthew A., Cazorla, M. Ángeles García, Morava, Eva, Bibi, Farah, Haider, Shahzad, Ferla, Matteo P., Taylor, Jenny C., Alsaif, Hessa S., Firdous, Abdulwahab, Hashem, Mais, Shashkin, Chingiz, Koneev, Kairgali, Kaiyrzhanov, Rauan, Efthymiou, Stephanie, Genomics, Queen Square, Schmitt‐Mechelke, Thomas, Ziegler, Andreas, Issa, Mahmoud Y., Elbendary, Hasnaa M., Striano, Pasquale, Alkuraya, Fowzan S. , Zaki, Maha S., Gleeson, Joseph G., Barakat, Tahsin Stefan, Bierau, Jorgen, Knaap, Marjo S. van der , Maroofian, Reza, Houlden, Henry, Houlden, Henry , Issa, Mahmoud Y. , Tort, Frederic , Efthymiou, Stéphanie , Bierau, Jörgen , Barakat, Tahsin Stefan , Maroofian, Reza , Ribes, Antonia , Alkuraya, Fowzan S , van der Knaap, Marjo S , Houlden, Henry , Maroofian, Reza , Scala, Marcello , Wortmann, Saskia , Kaya, Namik , Stellingwerff, Menno D., Pistorio, Angela , Glamuzina, Emma, Karnebeek, Clara D., Skrypnyk, Cristina, Iwanicka‐Pronicka, Katarzyna, Piekutowska‐Abramczuk, Dorota, Ciara, Elżbieta, Sheidley, Beth, Poduri, Annapurna, Jayakar, Parul, Jayakar, Anuj, Upadia, Jariya , Walano, Nicolette, Haack, Tobias B., Prokisch, Holger, Aldhalaan, Hesham , Karimiani, Ehsan G., Yıldız, Yılmaz , Ceylan, Ahmet Cevdet , Santiago‐Sim, Teresa, Dameron, Amy, Yang, Hui, Toosi, Mehran B., Ashrafzadeh, Farah, Akhondian, Javad, Imannezhad, Shima, Mirzadeh, Hanieh S., Maqbool, Shazia, Farid, Aisha, Al‐Muhaizea, Mohamed A., Alshwameen, Meznah O., Aldowsari, Lama, Alsagob, Maysoon, Alyousef, Ashwaq, AlMass, Rawan, Hargan, A. Al , Alwadei, Ali H., AlRasheed, Maha M., Çolak, Dilek , Alqudairy, Hanan, Khan, Sameena, Lines, Matthew A., Cazorla, M. Ángeles García, Morava, Eva, Bibi, Farah, Haider, Shahzad, Ferla, Matteo P., Taylor, Jenny C., Alsaif, Hessa S., Firdous, Abdulwahab, Hashem, Mais, Shashkin, Chingiz, Koneev, Kairgali, Kaiyrzhanov, Rauan, Genomics, Queen Square, Schmitt‐Mechelke, Thomas, Ziegler, Andreas, Issa, Mahmoud Y., Elbendary, Hasnaa M., Striano, Pasquale, Zaki, Maha S., Gleeson, Joseph G.

Mayo Clinic

Human Mutation | January 6, 2022 | Volume: 43 | Issue: 3 | Pages: 403-419

10.1002/humu.24326 | PMID 34989426 Get It

Neuroimaging phenotypes of CSF1R‐related leukoencephalopathy: Systematic review, meta‐analysis, and imaging recommendations
Mickeviciute, Goda‐Camille , Valiuskyte, Monika , Plattén, Michael , Wszołek, Zbigniew K. , Andersen, Oluf , Karrenbauer, Virginija Danylaité , Ineichen, Benjamin Victor , Danylaité Karrenbauer, Virginija , Ineichen, Benjamin V , Granberg, Tobias , Wszolek, Z.K.

Mayo Clinic

Journal of Internal Medicine | December 7, 2021 | Volume: 291 | Issue: 3 | Pages: 269-282

10.1111/joim.13420 | PMID 34875121 Get It

AbstractColony‐stimulating factor 1 receptor (CSF1R)‐related leukoencephalopathy is a rare but fatal microgliopathy. The diagnosis is often delayed due to multifaceted symptoms that can mimic several other neurological disorders. Imaging provides diagnostic clues that help identify cases. The objective of this study was to integrate the literature on neuroimaging phenotypes of CSF1R‐related leukoencephalopathy. A systematic review and meta‐analysis were performed for neuroimaging findings of CSF1R‐related leukoencephalopathy via PubMed, Web of Science, and Embase on 25 August 2021. The search included cases with confirmed CSF1R mutations reported under the previous terms hereditary diffuse leukoencephalopathy with spheroids, pigmentary orthochromatic leukodystrophy, and adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia. In 78 studies providing neuroimaging data, 195 cases were identified carrying CSF1R mutations in 14 exons and five introns. Women had a statistically significant earlier age of onset (p = 0.041, 40 vs 43 years). Mean delay between symptom onset and neuroimaging was 2.3 years. Main magnetic resonance imaging (MRI) findings were frontoparietal white matter lesions, callosal thinning, and foci of restricted diffusion. The hallmark computed tomography (CT) finding was white matter calcifications. Widespread cerebral hypometabolism and hypoperfusion were reported using positron emission tomography and single‐photon emission computed tomography. In conclusion, CSF1R‐related leukoencephalopathy is associated with progressive white matter lesions and brain atrophy that can resemble other neurodegenerative/‐inflammatory disorders. However, long‐lasting diffusion restriction and parenchymal calcifications are more specific findings that can aid the differential diagnosis. Native brain CT and brain MRI (with and without a contrast agent) are recommended with proposed protocols and pictorial examples are provided.
Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review
Asatryan, Babken , Landstrom, Andrew P. , Khanji, Mohammed Y , Odening, Katja E. , Gelzer, Anna R. , Semsarian, Christopher , Owens, Anjali , Chahal, C. Anwar A. , Asimaki, Angeliki , Landstrom, Andrew P , Khanji, Mohammed Yunus , Odening, Katja E , Gelzer, Anna R , Reichlin, Tobias , Chahal, Choudhary Anwar A , Asatryan, Babken , Asimaki, Angeliki , Cooper, Leslie T. , Marchlinski, Francis E.

Mayo Clinic

Circulation | November 15, 2021 | Volume: 144 | Issue: 20 | Pages: 1646-1655

10.1161/circulationaha.121.055890 | PMID 34780255 Get It

Arrhythmogenic cardiomyopathy (ACM) is a primary disease of the myocardium, predominantly caused by genetic defects in proteins of the cardiac intercalated disc, particularly, desmosomes. Transmission is mostly autosomal dominant with incomplete penetrance. ACM also has wide phenotype variability, ranging from premature ventricular contractions to sudden cardiac death and heart failure. Among other drivers and modulators of phenotype, inflammation in response to viral infection and immune triggers have been postulated to be an aggravator of cardiac myocyte damage and necrosis. This theory is supported by multiple pieces of evidence, including the presence of inflammatory infiltrates in more than two-thirds of ACM hearts, detection of different cardiotropic viruses in sporadic cases of ACM, the fact that patients with ACM often fulfill the histological criteria of active myocarditis, and the abundance of anti–desmoglein-2, antiheart, and anti-intercalated disk autoantibodies in patients with arrhythmogenic right ventricular cardiomyopathy. In keeping with the frequent familial occurrence of ACM, it has been proposed that, in addition to genetic predisposition to progressive myocardial damage, a heritable susceptibility to viral infections and immune reactions may explain familial clustering of ACM. Moreover, considerable in vitro and in vivo evidence implicates activated inflammatory signaling in ACM. Although the role of inflammation/immune response in ACM is not entirely clear, inflammation as a driver of phenotype and a potential target for mechanism-based therapy warrants further research. This review discusses the present evidence supporting the role of inflammatory and immune responses in ACM pathogenesis and proposes opportunities for translational and clinical investigation.
Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis
Berti, Alvise , Hillion, Sophie , Hummel, Amber M., Son, Young Min , Chriti, Nedra, Peikert, Tobias, Carmona, Eva M. , Abdulahad, Wayel H. , Heeringa, Peter , Harris, Kristina M. , Clair, E. William St. , Brunetta, Paul , Langford, Carol A. , Kallenberg, Cees G. M., Stone, John H. , Grandi, Guido , Cornec, Divi, Carmona, Eva M , Berti, Alvise , Fervenza, Fernando C. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Sun, Jie , Pers, Jacques-Olivier , Specks, Ulrich , Cornec, Divi

Mayo Clinic

JCI Insight | October 7, 2021 | Volume: 6 | Issue: 22 | Pages: No page available

10.1172/jci.insight.150999 | PMID 34618687 Get It

BACKGROUND Little is known about the autoreactive B cells in antineutrophil cytoplasmic antibody–associated (ANCA-associated) vasculitis (AAV). We aimed to investigate tolerance checkpoints of circulating antigen-specific proteinase 3–reactive (PR3 + ) B cells. METHODS Multicolor flow cytometry in combination with bioinformatics and functional in vitro studies were performed on baseline samples of PBMCs from 154 well-characterized participants of the RAVE trial (NCT00104299) with severely active PR3-AAV and myeloperoxidase-AAV (MPO-AAV) and 27 healthy controls (HCs). Clinical data and outcomes from the trial were correlated with PR3 + B cells (total and subsets). RESULTS The frequency of PR3 + B cells among circulating B cells was higher in participants with PR3-AAV (4.77% median [IQR, 3.98%–6.01%]) than in participants with MPO-AAV (3.16% median [IQR, 2.51%–5.22%]) and participants with AAV compared with HCs (1.67% median [IQR, 1.27%–2.16%], P < 0.001 for all comparisons), implying a defective central tolerance checkpoint in patients with AAV. Only PBMCs from participants with PR3-AAV contained PR3 + B cells capable of secreting PR3-ANCA IgG in vitro, proving they were functionally distinct from those of participants with MPO-AAV and HCs. Unsupervised clustering identified subtle subsets of atypical autoreactive PR3 + memory B cells accumulating through the maturation process in patients with PR3-AAV. PR3 + B cells were enriched in the memory B cell compartment of participants with PR3-AAV and were associated with higher serum CXCL13 levels, suggesting an increased germinal center activity. PR3 + B cells correlated with systemic inflammation (C-reactive protein and erythrocyte sedimentation rate, P < 0.05) and complete remission ( P < 0.001). CONCLUSION This study suggests the presence of defective central antigen-independent and peripheral antigen-dependent checkpoints in patients with PR3-AAV, elucidating the selection process of autoreactive B cells. Trial registration ClinicalTrials.gov NCT00104299. Funding The Vasculitis Foundation, the National Institute of Allergy and Infectious Diseases of the NIH, and the Mayo Foundation for Education and Research.
Acute Ischemic Priapism: An AUA/SMSNA Guideline
Bivalacqua, Trinity J. , Allen, Bryant , Brock, Gerald, Köhler, Tobias , Mulhall, John P. , Oristaglio, Jeff, Rahimi, Leila L., Rogers, Zora R. , Terlecki, Ryan , Trost, Landon , Yafi, Faysal A. , Bennett, Nelson , Broderick, Gregory A.

Mayo Clinic

Journal of Urology | September 8, 2021 | Volume: 206 | Issue: 5 | Pages: 1114-1121

10.1097/ju.0000000000002236 | PMID 34495686 Get It

Thrombus Histology as It Relates to Mechanical Thrombectomy: A Meta-Analysis and Systematic Review
Bhambri, Ankur, Adapa, Arjun R. , Liu, Yang , Boeckh‐Behrens, Tobias , Procházka, Václav , Hernández‐Fernández, Francisco , Hashimoto, Tetsuya , Chaudhary, Neeraj , Savastano, Luis E., Chaudhary, Neeraj , Pandey, Aditya S , Liu, Yang , Barbella-Aponte, Rosa Angélica , Savastano, Luis , Gemmete, Joseph John , Shih, Albert J.

Mayo Clinic

Neurosurgery | September 8, 2021 | Volume: 89 | Issue: 6 | Pages: 1122-1131

10.1093/neuros/nyab366 | PMID 34634805 Get It

Abstract BACKGROUND Appropriate thrombus-device interaction is critical for recanalization. Histology can serve as a proxy for mechanical properties, and thus inform technique selection. OBJECTIVE To investigate the value of histologic characterization, we conducted a systematic review and meta-analysis on the relationship between thrombus histology and recanalization, technique, etiology, procedural efficiency, and imaging findings. METHODS In this meta-analysis, we identified studies published between March 2010 and March 2020 reporting findings related to the histologic composition of thrombi in large vessel occlusion stroke. Studies with at least 10 patients who underwent mechanical thrombectomy using stent retriever or aspiration were considered. Only studies in which retrieved thrombi were histologically processed were included. Patient-level data were requested when data could not be directly extracted. The primary outcome assessed was the relationship between thrombus histology and angiographic outcome. RESULTS A total of 22 studies encompassing 1623 patients met inclusion criteria. Clots associated with good angiographic outcome had higher red blood cell (RBC) content (mean difference [MD] 9.60%, 95% CI 3.85-15.34, P = .008). Thrombi retrieved by aspiration had less fibrin (MD −11.39, 95% CI −22.50 to −0.27, P = .046) than stent-retrieved thrombi. Fibrin/platelet-rich clots were associated with longer procedure times (MD 13.20, 95% CI 1.30-25.10, P = .037). Hyperdense artery sign was associated with higher RBC content (MD 14.17%, 95% CI 3.07-25.27, P = .027). No relationship was found between composition and etiology. CONCLUSION RBC-rich thrombi were associated with better recanalization outcomes and shorter procedure times, suggesting that preinterventional compositional characterization may yield important prognostic and therapeutic guidance.